Xeris Biopharma Holdings (XERS) Amortization - Intangibles (2021 - 2026)

Xeris Biopharma Holdings (XERS) has reported Amortization - Intangibles for 6 consecutive years, with $2.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Amortization - Intangibles changed 0.0% year-over-year to $2.7 million; the trailing twelve-month figure through Jun 2026 stood at $10.8 million (changed 0.0% YoY), and the FY2025 full-year result was $10.8 million, changed 0.0% from the prior year.
• Amortization - Intangibles steadied at $2.7 million in Q2 2026 per XERS's latest filing, from $2.7 million in the prior quarter.
• Across five years, Amortization - Intangibles topped out at $2.7 million in Q1 2022 and bottomed at $2.7 million in Q2 2022.
• Historically, Amortization - Intangibles has averaged $2.7 million across 5 years, with a median of $2.7 million in 2022.
• The sharpest annual moves came in 2022 and 2025: Amortization - Intangibles surged 392.91% in 2022, then dropped 0.04% in 2025.
• Over 5 years, Amortization - Intangibles stood at $2.7 million in 2022, then changed by 0.0% to $2.7 million in 2023, then changed by 0.0% to $2.7 million in 2024, then changed by 0.0% to $2.7 million in 2025, then changed by 0.0% to $2.7 million in 2026.
• According to Business Quant data, Amortization - Intangibles over the past three periods registered $2.7 million, $2.7 million, and $2.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.